XORTX Strengthens Executive Team
December 19, 2024 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Presentation at the Rare and Genetic Disease Summit
December 12, 2024 09:17 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
October 24, 2024 07:00 ET
|
XORTX Therapeutics Inc.
● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats, mice and humans ● CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX...
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
October 18, 2024 16:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
October 17, 2024 08:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Initiates Precision Medicine Program
October 09, 2024 05:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 09, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Results of Annual and Special Meeting of Shareholders
September 13, 2024 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
September 12, 2024 17:30 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
September 06, 2024 17:30 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
September 03, 2024 12:30 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...